Mark Stead

Mark Stead, PhD, serves as the Head of Business Development at Atomic AI since January 2024, focusing on leveraging artificial intelligence for RNA biology and advancing novel therapeutics. Prior to this role, Mark held the position of Senior Business Development Director at Exelixis, where responsibilities included negotiating partnerships to enhance cancer treatment innovations. As Director of Alliance Management at Kite Pharma, Mark managed key corporate relationships, including alliances in Japan and China. Earlier roles at Amgen encompassed both business development and research, with a focus on engineered large molecule therapeutics and drug discovery processes. Mark began their career at the Albert Einstein College of Medicine, leading a molecular biology team in a structural genomics initiative. Mark holds a Ph.D. in Genetics from The University of Georgia and a B.S. in Biology from Saint Martin's University.